Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

NCT06062485 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School